ARTICLE | Clinical News
Enterome's CD candidate well tolerated in Phase I
November 30, 2017 11:46 PM UTC
Enterome Bioscience S.A. (Paris, France) reported data from a Phase I trial in about 60 healthy volunteers showing that single and multiple ascending oral doses of Crohn's disease candidate EB8018 (EP8018) were well tolerated.
The double-blind, placebo-controlled, U.K. trial's primary endpoint is safety. Secondary endpoints include pharmacokinetics and microbiome richness...